2022
DOI: 10.17219/acem/144993
|View full text |Cite
|
Sign up to set email alerts
|

Rifaximin in gut microbiota modification in acute pancreatitis: 15 years of retrospective clinical study

Abstract: Background. Gut decontamination could have some benefits in preventing infectious complications in acute pancreatitis (AP).Objectives. To investigate whether the administration of rifaximin could have an impact on the outcomes of AP. Materials and methods.We conducted a retrospective study on 373 patients with a median age of 50 years that were admitted to our Department of Gastroenterology in the years 2001-2016 with a diagnosis of AP. Patients were subclassified according to the revised Atlanta criteria: mil… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…[4,5] The combination of drugs may prevent complications, but the impact on mortality is unknown. [6] Clinical trials for several drugs, including, rifadxmin, [7] pentoxifylline, [8] and auxora [9] are underway. Although these drugs can improve emergency conditions, their safety profile and effect on preventing complications warrant further investigations.…”
Section: Introductionmentioning
confidence: 99%
“…[4,5] The combination of drugs may prevent complications, but the impact on mortality is unknown. [6] Clinical trials for several drugs, including, rifadxmin, [7] pentoxifylline, [8] and auxora [9] are underway. Although these drugs can improve emergency conditions, their safety profile and effect on preventing complications warrant further investigations.…”
Section: Introductionmentioning
confidence: 99%